An experimental drug for those with a severe form of multiple sclerosis reduced the risk of the disease progressing by 21 percent, according to new research.
Swiss drugmaker Novartis AG said its experimental medicine for people with a severe form of multiple sclerosis could be a blockbuster after a study showed that the treatment reduced the risk of the disease progressing by 21 percent.
The oral drug siponimod could be prescribed for patients with a highly disabling form of multiple sclerosis for which there are very few treatment options, Novartis said in a statement on Saturday. The company in August said the drug met its target for reducing the risk of the disability progression in a late-stage study.
“This population hasn’t had an effective therapy,” Vasant Narasimhan, chief medical officer for Novartis, said in a phone interview. “For the first time, we have a medicine that can slow the progression of this disease in a proportion of these patients, so we view it as a significant breakthrough.”
Read Full Article: Novartis Drug for Multiple Sclerosis Shows Reduction in Risks – Bloomberg
|Read Full Article: Novartis Drug for Multiple Sclerosis Shows Reduction in Risks – Bloomberg|